免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

臨床試験

Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume

NCT: NCT07528781 · RECRUITING

NCT識別子NCT07528781
ステータスRECRUITING
開始日2026-03-17
完了2028-04-01

概要

The goal of this observational study is demonstrate that a novel artificial intelligence based software for the quantification of the mitral regurgitation on 3-dimensional transesophageal echocardiography (3D CFQ) is more reproducible and accurate than the conventional assessment of mitral regurgitation performed with 2-dimensional echocardiography. The main question aims to answer is to demonstrate the agreement between 3D-CFQ measurement of the mitral regurgitant volume and the cardiac magnetic resonance measurement of the regurgitant volume is better than the agreement between 2-dimensional echocardiography and cardiac magnetic resonance. If this is demonstrated, we would like to test the accuracy of this tool to be applied in acute settings such as transcatheter interventions to decide the therapy to follow. Participants will undergo clinically indicated transesophageal echocardiography to characterize the mechanism and severity of mitral regurgitation and to cardiac magnetic resonance to be used as reference stadard to define the mitral regurgitation severity.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。

↑